Ebola viral dynamics in vivo and the antiviral efficacy of Favipiravir: from small animals to human clinical trial.
The main objective of this workpackage is the analysis of the data from WP1 (humans) and WP3 (non-human primates) to provide a quantitative understanding of the determinants of the viro-immunologic response to treatment.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France):
Prof. Jeremie Guedj (WP lead), Prof. France Mentré
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (Germany):
Prof. Stephan Günther
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG (Germany) :
Dr. Frederik Graw
UNIVERSITEIT UTRECHT (The Netherlands):
Prof. Rob de Boer